HALO — Halozyme Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual balance sheet for Halozyme Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	421	368	741	363	336
Net Total Accounts Receivable
Net Total Receivables	59.4	97.7	91	231	234
Total Inventory
Prepaid Expenses
Total Current Assets	543	555	926	739	746
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	10.9	10.6	8.79	75.6	74.9
Net Goodwill
Net Intangible Assets
Other Long Term Assets
Total Assets	566	580	1,104	1,842	1,733
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	85.6	421	117	131	112
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	474	429	907	1,672	1,649
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	91.8	151	197	170	83.8
Total Liabilities & Shareholders' Equity	566	580	1,104	1,842	1,733
Total Common Shares Outstanding